GPER-MEDIATED REGULATION of NUCLEAR AKT/FOXO3A SIGNALING Erin Zekas

Total Page:16

File Type:pdf, Size:1020Kb

GPER-MEDIATED REGULATION of NUCLEAR AKT/FOXO3A SIGNALING Erin Zekas University of New Mexico UNM Digital Repository Biomedical Sciences ETDs Electronic Theses and Dissertations 7-1-2014 GPER-MEDIATED REGULATION OF NUCLEAR AKT/FOXO3A SIGNALING Erin Zekas Follow this and additional works at: https://digitalrepository.unm.edu/biom_etds Recommended Citation Zekas, Erin. "GPER-MEDIATED REGULATION OF NUCLEAR AKT/FOXO3A SIGNALING." (2014). https://digitalrepository.unm.edu/biom_etds/153 This Dissertation is brought to you for free and open access by the Electronic Theses and Dissertations at UNM Digital Repository. It has been accepted for inclusion in Biomedical Sciences ETDs by an authorized administrator of UNM Digital Repository. For more information, please contact [email protected]. Erin Zekas Candidate Biomedical Sciences Department This dissertation is approved, and it is acceptable in quality and form for publication: Approved by the Dissertation Committee: Eric R. Prossnitz, PhD, Chairperson Angela Wandinger-Ness, PhD Diane Lidke, PhD Helen J. Hathaway, PhD i GPER-MEDIATED REGULATION OF NUCLEAR AKT/FOXO3A SIGNALING by ERIN ZEKAS B.S. Biology, Temple University, 2005 DISSERTATION Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Biomedical Sciences The University of New Mexico Albuquerque, New Mexico July, 2014 ii © 2014, Erin Zekas iii ACKNOWLEDGEMENTS First and foremost, I would like to thank my parents, Marlene and Joe. They have unconditionally supported me throughout this experience and throughout my entire life and for that I am more grateful than words could express. Secondly, I would like to thank my mentor, Dr. Eric Prossnitz, for pushing me to stand on my own two feet as a researcher. I would also particularly like to thank Eric for his patience. Seriously. I’ve learned so much throughout this process and have Eric to thank for helping me make it out of this in one piece. Next, I would like to acknowledge my committee. Dr. Angela Wandinger-Ness has always put things in perspective for me. Angela has also been extremely helpful with my job search and giving of her time and advice. I am truly grateful for that. Dr. Diane Lidke has been a useful asset with regards to image analysis. Diane’s expert input was always welcome and I thank her for being so helpful. Lastly, I would like to thank Dr. Helen Hathaway, who only recently joined my committee but has been a mentor to me since I started this program. Helen’s guidance and understanding have kept me sane. I would like to thank all my coworkers and fellow classmates. Dr. Niki Marjon, Dr. Sara Alcon and Dr. Allison Scaling who have always been supportive and who I still ask for help despite them all having moved on. I am also extremely grateful to Dr. Geetanjali Sharma and Tamara Howard. Gee has been so helpful in the lab and always there when I need someone to vent to. I probably wouldn’t have made it through this last year without Tamara. Every time I would go on the Leica iv and return with a new problem, Tamara would have at least five ideas about how to fix it. I am so thankful for my friends in Albuquerque as well as my friends and family back home. It’s been a long 5 years and they have always been there for me when I need them. I also need to thank my former mentor, Dr. Sriram Krishnaswamy. Krish was the first person in science to give me a chance despite having no experience. I also didn’t really have a clue what I wanted to do with my life. He gave me my own project and allowed me to fall on my face repeatedly for 2 years before things finally clicked. Krish then told me I needed to move on to either graduate school or something else. Here I am 5 years later in Albuquerque, New Mexico finishing my PhD, all because of Krish and his old friend Walt Keisel. I am so grateful to Krish for his amazing and brutally honest support throughout the past 9 years. Finally, I would like to acknowledge the Spatial Temporal Modeling Center (P50 GM085273 (Wilson, PI)) at the University of New Mexico and NIH CA163890 (Prossnitz, PI) for providing funding for this project. v GPER-MEDIATED REGULATION OF NUCLEAR AKT/FOXO3A SIGNALING By Erin Zekas B.S., Biology, Temple University, 2005 Ph.D., Biomedical Sciences, University of New Mexico, 2014 ABSTRACT 17β-estradiol (estrogen) has been demonstrated to regulate survival in breast cancer cells, which is partially mediated by its nuclear receptors ERα and ERβ and the G protein-coupled estrogen receptor (GPER). We previously established that estrogen can activate the phosphoinositide 3-kinase (PI3Kinase) prosurvival pathway via GPER stimulation resulting in PIP3 generation within the nucleus of breast cancer cells; the mechanism for this is still unclear. PIP3 generation results in Akt activation, which is known to inactivate FOXO3a, a proapoptotic transcription factor that translocates from the nucleus to the cytoplasm upon inactivation resulting in a decrease in proapoptotic gene expression and consequently an increase in cell survival. Here, utilizing a FoxO3-GFP construct, we report FOXO3a inactivation as a result of GPER stimulation by E2 and the GPER-selective agonist G-1 in the estrogen-responsive breast cancer cell line MCF7 and that ERα is not required. The p110α catalytic subunit of PI3Kinase, vi and the transactivation of the EGFR constitute the mechanism by which GPER inactivation of FOXO3a occurs. Additionally, E2 and G-1 stimulation of MCF7 cells results in a decrease in caspase activation compared to negative control. This suggests, in part, that GPER stimulation is required for survival of breast cancer cells and that GPER expression and FOXO3a localization should be utilized as prognostic markers in breast cancer treatments. Furthermore, our results indicate a need for GPER antagonists in GPER positive breast cancers in order to counteract GPER related prosurvival effects in combination with chemotherapeutic drug treatments. vii TABLE OF CONTENTS ABSTRACT...................................................................................................................... vi LIST OF FIGURES .......................................................................................................... x LIST OF ABBERVIATIONS ......................................................................................... xii CHAPTER 1 ...................................................................................................................... 1 1. Introduction ................................................................................................................. 1 1.1. Estrogen Synthesis ............................................................................................... 1 1.2. Estrogen Function ................................................................................................. 4 1.3. Estrogen Receptors and Genomic Signaling ................................................. 5 1.4. Estrogen Receptors and Nongenomic Signaling ........................................ 10 1.5. PI3Kinase ................................................................................................................ 15 1.6. FOX Proteins ......................................................................................................... 19 1.7. PI3Kinase/Akt/FOXO and Cancer ..................................................................... 22 1.8. Breast Cancer ........................................................................................................ 25 1.9. GPER-selective ligands ...................................................................................... 27 Rationale......................................................................................................................... 30 Hypothesis ..................................................................................................................... 30 Specific Aims ................................................................................................................ 30 CHAPTER 2 .................................................................................................................... 32 2. GPER activation leads to FOXO3a inactivation in MCF7 breast cancer cells.................................................................................................................................. 32 2.1. Abstract................................................................................................................... 32 2.2. Introduction ........................................................................................................... 33 viii 2.3. Materials and Methods ........................................................................................ 37 2.3. Results .................................................................................................................... 42 2.4. Discussion ............................................................................................................. 50 CHAPTER 3 .................................................................................................................... 82 3. Conclusions, significance and future directions ............................................ 82 3.1. Conclusions ........................................................................................................... 82 3.2. Significance ........................................................................................................... 88 3.3. Future directions .................................................................................................
Recommended publications
  • The Title of the Dissertation
    UNIVERSITY OF CALIFORNIA SAN DIEGO Novel network-based integrated analyses of multi-omics data reveal new insights into CD8+ T cell differentiation and mouse embryogenesis A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Bioinformatics and Systems Biology by Kai Zhang Committee in charge: Professor Wei Wang, Chair Professor Pavel Arkadjevich Pevzner, Co-Chair Professor Vineet Bafna Professor Cornelis Murre Professor Bing Ren 2018 Copyright Kai Zhang, 2018 All rights reserved. The dissertation of Kai Zhang is approved, and it is accept- able in quality and form for publication on microfilm and electronically: Co-Chair Chair University of California San Diego 2018 iii EPIGRAPH The only true wisdom is in knowing you know nothing. —Socrates iv TABLE OF CONTENTS Signature Page ....................................... iii Epigraph ........................................... iv Table of Contents ...................................... v List of Figures ........................................ viii List of Tables ........................................ ix Acknowledgements ..................................... x Vita ............................................. xi Abstract of the Dissertation ................................. xii Chapter 1 General introduction ............................ 1 1.1 The applications of graph theory in bioinformatics ......... 1 1.2 Leveraging graphs to conduct integrated analyses .......... 4 1.3 References .............................. 6 Chapter 2 Systematic
    [Show full text]
  • The DNA Methylation of FOXO3 and TP53 As a Blood Biomarker of Late
    Yuan et al. J Transl Med (2020) 18:467 https://doi.org/10.1186/s12967-020-02643-y Journal of Translational Medicine RESEARCH Open Access The DNA methylation of FOXO3 and TP53 as a blood biomarker of late-onset asthma Lin Yuan1,2,3, Leyuan Wang2, Xizi Du2, Ling Qin1,3, Ming Yang4, Kai Zhou2, Mengping Wu2, Yu Yang2, Zhiyuan Zheng1,3, Yang Xiang2, Xiangping Qu2, Huijun Liu2, Xiaoqun Qin2 and Chi Liu1,2,5* Abstract Background: Late-onset asthma (LOA) is beginning to account for an increasing proportion of asthma patients, which is often underdiagnosed in the elderly. Studies on the possible relations between aging-related genes and LOA contribute to the diagnosis and treatment of LOA. Forkhead Box O3 (FOXO3) and TP53 are two classic aging-related genes. DNA methylation varies greatly with age which may play an important role in the pathogenesis of LOA. We supposed that the diferentially methylated sites of FOXO3 and TP53 associated with clinical phenotypes of LOA may be useful biomarkers for the early screening of LOA. Methods: The mRNA expression and DNA methylation of FOXO3 and TP53 in peripheral blood of 43 LOA patients (15 mild LOA, 15 moderate LOA and 13 severe LOA) and 60 healthy controls (HCs) were determined. The association of methylated sites with age was assessed by Cox regression to control the potential confounders. Then, the correlation between diferentially methylated sites (DMSs; p-value < 0.05) and clinical lung function in LOA patients was evalu- ated. Next, candidate DMSs combining with age were evaluated to predict LOA by receiver operating characteristic (ROC) analysis and principal components analysis (PCA).
    [Show full text]
  • The E–Id Protein Axis Modulates the Activities of the PI3K–AKT–Mtorc1
    Downloaded from genesdev.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press The E–Id protein axis modulates the activities of the PI3K–AKT–mTORC1– Hif1a and c-myc/p19Arf pathways to suppress innate variant TFH cell development, thymocyte expansion, and lymphomagenesis Masaki Miyazaki,1,8 Kazuko Miyazaki,1,8 Shuwen Chen,1 Vivek Chandra,1 Keisuke Wagatsuma,2 Yasutoshi Agata,2 Hans-Reimer Rodewald,3 Rintaro Saito,4 Aaron N. Chang,5 Nissi Varki,6 Hiroshi Kawamoto,7 and Cornelis Murre1 1Department of Molecular Biology, University of California at San Diego, La Jolla, California 92093, USA; 2Department of Biochemistry and Molecular Biology, Shiga University of Medical School, Shiga 520-2192, Japan; 3Division of Cellular Immunology, German Cancer Research Center, D-69120 Heidelberg, Germany; 4Department of Medicine, University of California at San Diego, La Jolla, California 92093, USA; 5Center for Computational Biology, Institute for Genomic Medicine, University of California at San Diego, La Jolla, California 92093, USA; 6Department of Pathology, University of California at San Diego, La Jolla, California 92093, USA; 7Department of Immunology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan It is now well established that the E and Id protein axis regulates multiple steps in lymphocyte development. However, it remains unknown how E and Id proteins mechanistically enforce and maintain the naı¨ve T-cell fate. Here we show that Id2 and Id3 suppressed the development and expansion of innate variant follicular helper T (TFH) cells. Innate variant TFH cells required major histocompatibility complex (MHC) class I-like signaling and were associated with germinal center B cells.
    [Show full text]
  • A Flexible Microfluidic System for Single-Cell Transcriptome Profiling
    www.nature.com/scientificreports OPEN A fexible microfuidic system for single‑cell transcriptome profling elucidates phased transcriptional regulators of cell cycle Karen Davey1,7, Daniel Wong2,7, Filip Konopacki2, Eugene Kwa1, Tony Ly3, Heike Fiegler2 & Christopher R. Sibley 1,4,5,6* Single cell transcriptome profling has emerged as a breakthrough technology for the high‑resolution understanding of complex cellular systems. Here we report a fexible, cost‑efective and user‑ friendly droplet‑based microfuidics system, called the Nadia Instrument, that can allow 3′ mRNA capture of ~ 50,000 single cells or individual nuclei in a single run. The precise pressure‑based system demonstrates highly reproducible droplet size, low doublet rates and high mRNA capture efciencies that compare favorably in the feld. Moreover, when combined with the Nadia Innovate, the system can be transformed into an adaptable setup that enables use of diferent bufers and barcoded bead confgurations to facilitate diverse applications. Finally, by 3′ mRNA profling asynchronous human and mouse cells at diferent phases of the cell cycle, we demonstrate the system’s ability to readily distinguish distinct cell populations and infer underlying transcriptional regulatory networks. Notably this provided supportive evidence for multiple transcription factors that had little or no known link to the cell cycle (e.g. DRAP1, ZKSCAN1 and CEBPZ). In summary, the Nadia platform represents a promising and fexible technology for future transcriptomic studies, and other related applications, at cell resolution. Single cell transcriptome profling has recently emerged as a breakthrough technology for understanding how cellular heterogeneity contributes to complex biological systems. Indeed, cultured cells, microorganisms, biopsies, blood and other tissues can be rapidly profled for quantifcation of gene expression at cell resolution.
    [Show full text]
  • Regulation of PERK Expression by FOXO3: a Vulnerability of Drug- Resistant Cancer Cells
    Oncogene (2019) 38:6382–6398 https://doi.org/10.1038/s41388-019-0890-7 ARTICLE Regulation of PERK expression by FOXO3: a vulnerability of drug- resistant cancer cells 1 1 1 1 1 Glowi Alasiri ● Yannasittha Jiramongkol ● Stefania Zona ● Lavender Y. -N. Fan ● Zimam Mahmud ● 2 2 1 Gyungyub Gong ● Hee Jin Lee ● Eric W. -F. Lam Received: 15 February 2019 / Revised: 28 June 2019 / Accepted: 2 July 2019 / Published online: 16 July 2019 © The Author(s) 2019. This article is published with open access Abstract The major impediment to effective cancer therapy has been the development of drug resistance. The tumour suppressive transcription factor FOXO3 promotes cell cycle arrest, senescence and cell death, and mediates the cytotoxic and cytostatic functions of cancer therapeutics. In consequence, FOXO3 is often downregulated as an adaptive response in cancer and particularly in chemotherapeutic drug-resistant cells. Consistently, we find that FOXO3 expression is attenuated in the drug- resistant MCF-7-EpiR and MCF-7-TaxR compared to the parental MCF-7 breast cancer cells. Using ChIP, short-interfering RNA (siRNA) knockdown, and overexpression assays as well as Foxo1/3/4−/− MEFs, we establish the endoplasmic reticulum 1234567890();,: 1234567890();,: (ER)-stress defence modulator PERK (eIF2AK3) as a direct downstream transcriptional target of FOXO3. In agreement, there is also a positive correlation between FOXO3 and PERK expression at the protein and RNA levels in breast cancer patient samples. We uncover that PERK expression is downregulated but its activity constitutively elevated in the drug- resistant cells. With this in mind, we exploit this adaptive response of low FOXO3 and PERK expression, and high PERK activity in drug-resistant breast cancer cells and show that these drug-resistant cells are specifically sensitive to PERK inhibition.
    [Show full text]
  • Genequery™ Human Stem Cell Transcription Factors Qpcr Array
    GeneQuery™ Human Stem Cell Transcription Factors qPCR Array Kit (GQH-SCT) Catalog #GK125 Product Description ScienCell's GeneQuery™ Human Stem Cell Transcription Factors qPCR Array Kit (GQH-SCT) surveys a panel of 88 transcription factors related to stem cell maintenance and differentiation. Transcription factors are proteins that can regulate target gene transcription level by binding to specific regions of the genome known as enhancers or silencers. Brief examples of how genes may be grouped according to their functions are shown below: • Pluripotency transcription factors: NANOG, POU5F1, SOX2 • Embryonic development: EOMES, FOXC2/D3/O1, HOXA9/A10, KLF2/5, LIN28B, MAX, PITX2, SMAD1, TBX5, ZIC1 • Germ layer formation and differentiation: FOXA2, GATA6, HAND1, ISL1, KLF4, SMAD2, SOX9 • Organ morphogenesis: EZH2, HOXA11/B3/B5/C9, MSX2, MYC, PAX5/8, VDR • Angiogenesis: CDX2, JUN, NR2F2, RUNX1, WT1 • Hematopoiesis and osteogenesis: EGR3, ESR1, GATA1/2/3, GLI2, NFATC1, PAX9, RB1, SOX6, SP1, STAT1 • Neural stem cell maintenance and differentiation: ATF2, CREB1, FOSB, FOXO3, HES1, HOXD10, MCM2/7, MEF2C, NEUROD1/G1, OLIG1/2, PAX3/6, POU4F1, PPARG, SMAD3/4, SNAI1, STAT3 Note : all gene names follow their official symbols by the Human Genome Organization Gene Nomenclature Committee (HGNC). GeneQuery™ qPCR array kits are qPCR ready in a 96-well plate format, with each well containing one primer set that can specifically recognize and efficiently amplify a target gene's cDNA. The carefully designed primers ensure that: (i) the optimal annealing temperature in qPCR analysis is 65°C (with 2 mM Mg 2+ , and no DMSO); (ii) the primer set recognizes all known transcript variants of target gene, unless otherwise indicated; and (iii) only one gene is amplified.
    [Show full text]
  • In Vitro Targeting of Transcription Factors to Control the Cytokine Release Syndrome in 2 COVID-19 3
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424728; this version posted December 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 In vitro Targeting of Transcription Factors to Control the Cytokine Release Syndrome in 2 COVID-19 3 4 Clarissa S. Santoso1, Zhaorong Li2, Jaice T. Rottenberg1, Xing Liu1, Vivian X. Shen1, Juan I. 5 Fuxman Bass1,2 6 7 1Department of Biology, Boston University, Boston, MA 02215, USA; 2Bioinformatics Program, 8 Boston University, Boston, MA 02215, USA 9 10 Corresponding author: 11 Juan I. Fuxman Bass 12 Boston University 13 5 Cummington Mall 14 Boston, MA 02215 15 Email: [email protected] 16 Phone: 617-353-2448 17 18 Classification: Biological Sciences 19 20 Keywords: COVID-19, cytokine release syndrome, cytokine storm, drug repurposing, 21 transcriptional regulators 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424728; this version posted December 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 22 Abstract 23 Treatment of the cytokine release syndrome (CRS) has become an important part of rescuing 24 hospitalized COVID-19 patients. Here, we systematically explored the transcriptional regulators 25 of inflammatory cytokines involved in the COVID-19 CRS to identify candidate transcription 26 factors (TFs) for therapeutic targeting using approved drugs.
    [Show full text]
  • Tissue-Specific Metabolic Regulation of FOXO-Binding Protein
    cells Review Tissue-Specific Metabolic Regulation of FOXO-Binding Protein: FOXO Does Not Act Alone Noriko Kodani 1 and Jun Nakae 2,* 1 Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan; [email protected] 2 Department of Physiology, International University of Health and Welfare School of Medicine, Narita 286-8686, Japan * Correspondence: [email protected]; Tel.: +81-476-20-7701 Received: 17 January 2020; Accepted: 10 March 2020; Published: 13 March 2020 Abstract: The transcription factor forkhead box (FOXO) controls important biological responses, including proliferation, apoptosis, differentiation, metabolism, and oxidative stress resistance. The transcriptional activity of FOXO is tightly regulated in a variety of cellular processes. FOXO can convert the external stimuli of insulin, growth factors, nutrients, cytokines, and oxidative stress into cell-specific biological responses by regulating the transcriptional activity of target genes. However, how a single transcription factor regulates a large set of target genes in various tissues in response to a variety of external stimuli remains to be clarified. Evidence indicates that FOXO-binding proteins synergistically function to achieve tightly controlled processes. Here, we review the elaborate mechanism of FOXO-binding proteins, focusing on adipogenesis, glucose homeostasis, and other metabolic regulations in order to deepen our understanding and to identify a novel therapeutic target for the prevention and treatment of metabolic disorders. Keywords: FOXO; transcription factor; FOXO-binding protein 1. Introduction Forkhead box (FOXO) transcription factors play important roles in apoptosis, the cell cycle, DNA damage repair, oxidative stress, cell differentiation, glucose metabolism, and other cellular functions [1].
    [Show full text]
  • Examining New Interactors of Notch/Rbpjκ Signalling in Adult
    TECHNISCHE UNIVERSITÄT MÜNCHEN Lehrstuhl Entwicklungsgenetik Examining new interactors of Notch/RBPJ signalling in adult neural stem cells Dissertation von Tobias Johannes Schwarz Helmholtz Zentrum München Institut für Entwicklungsgenetik TECHNISCHE UNIVERSITÄT MÜNCHEN Lehrstuhl Entwicklungsgenetik Examining new interactors of Notch/RBPJ signalling in adult neural stem cells Tobias Johannes Schwarz Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzende: Univ.-Prof. A. Schnieke, Ph.D. Prüfer der Dissertation: 1. Univ.-Prof. Dr. W. Wurst 2. Univ.-Prof. Dr. C. Lie, (Friedrich-Alexander Universität Erlangen-Nürnberg) Die Dissertation wurde am 20. 03. 2012 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 25. 07. 2012 angenommen. Table of contents 1 Zusammenfassung......................................................................................... 4 2 Summary .......................................................................................................... 6 3 Introduction ...................................................................................................... 7 3.1 Adult neurogenesis and neural stem cells ..................................................... 7 3.2 Signal integration by adult neural stem cells
    [Show full text]
  • Positional Specificity of Different Transcription Factor Classes Within Enhancers
    Positional specificity of different transcription factor classes within enhancers Sharon R. Grossmana,b,c, Jesse Engreitza, John P. Raya, Tung H. Nguyena, Nir Hacohena,d, and Eric S. Landera,b,e,1 aBroad Institute of MIT and Harvard, Cambridge, MA 02142; bDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139; cProgram in Health Sciences and Technology, Harvard Medical School, Boston, MA 02215; dCancer Research, Massachusetts General Hospital, Boston, MA 02114; and eDepartment of Systems Biology, Harvard Medical School, Boston, MA 02215 Contributed by Eric S. Lander, June 19, 2018 (sent for review March 26, 2018; reviewed by Gioacchino Natoli and Alexander Stark) Gene expression is controlled by sequence-specific transcription type-restricted enhancers (active in <50% of the cell types) and factors (TFs), which bind to regulatory sequences in DNA. TF ubiquitous enhancers (active in >90% of the cell types) (SI Ap- binding occurs in nucleosome-depleted regions of DNA (NDRs), pendix, Fig. S1C). which generally encompass regions with lengths similar to those We next sought to infer functional TF-binding sites within the protected by nucleosomes. However, less is known about where active regulatory elements. In a recent study (5), we found that within these regions specific TFs tend to be found. Here, we char- TF binding is strongly correlated with the quantitative DNA acterize the positional bias of inferred binding sites for 103 TFs accessibility of a region. Furthermore, the TF motifs associated within ∼500,000 NDRs across 47 cell types. We find that distinct with enhancer activity in reporter assays in a cell type corre- classes of TFs display different binding preferences: Some tend to sponded closely to those that are most enriched in the genomic have binding sites toward the edges, some toward the center, and sequences of active regulatory elements in that cell type (5).
    [Show full text]
  • FOXO Transcription Factors Control E2F1 Transcriptional Specificity and Apoptotic Function
    Published OnlineFirst August 21, 2013; DOI: 10.1158/0008-5472.CAN-13-0453 Cancer Tumor and Stem Cell Biology Research FOXO Transcription Factors Control E2F1 Transcriptional Specificity and Apoptotic Function Igor Shats1, Michael L. Gatza1, Beiyu Liu1, Steven P. Angus1, Lingchong You2, and Joseph R. Nevins1 Abstract The transcription factor E2F1 is a key regulator of proliferation and apoptosis but the molecular mechanisms that mediate these cell fate decisions remain unclear. Here, we identify FOXO transcription factors as E2F1 target genes that act in a feed-forward regulatory loop to reinforce gene induction of multiple apoptotic genes. We found that E2F1 forms a complex with FOXO1 and FOXO3. RNAi-mediated silencing of FOXO impaired E2F1 binding to the promoters of cooperative target genes. A FOXO3 mutant insensitive to inactivation by survival kinases rescued the inhibitory effect of growth factor signaling on E2F1-mediated transcription and apoptosis. The E2F1/ FOXO axis is frequently blocked in cancer, as evidenced by the specific downregulation of the FOXO-dependent E2F1 transcriptional program in multiple cancer types and by the association of a reduced E2F1/FOXO transcriptional program with poor prognosis. HDAC and phosphoinositide 3-kinase (PI3K) inhibitors were identified as specific activators of E2F1/FOXO transcription, acting to enhance E2F1-induced apoptosis in a FOXO3-dependent manner. Notably, combining the histone deacetylase inhibitor vorinostat with a PI3K inhibitor led to enhanced FOXO-dependent apoptosis. Collectively, our results identify E2F1/FOXO cooperation as a regulatory mechanism that places E2F1 apoptotic activity under the control of survival signaling. Therapeutic reactivation of this tumor suppressive mechanism may offer a novel broad-acting therapy for cancer.
    [Show full text]
  • Foxo3a As a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer
    cancers Article FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer 1, 1, 2, 1, 1, Michele Pellegrino y, Pietro Rizza y, Ada Donà y, Alessandra Nigro y, Elena Ricci y, Marco Fiorillo 3, Ida Perrotta 4, Marilena Lanzino 1, Cinzia Giordano 1, Daniela Bonofiglio 1 , 1 3 3 1, , Rosalinda Bruno , Federica Sotgia , Michael P. Lisanti , Diego Sisci * z and 1, , Catia Morelli * z 1 Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, 87036 Cosenza, Italy; [email protected] (M.P.); [email protected] (P.R.); [email protected] (A.N.); [email protected] (E.R.); [email protected] (M.L.); [email protected] (C.G.); daniela.bonofi[email protected] (D.B.); [email protected] (R.B.) 2 Department of Hematologic Malignancies Translational Science, Beckman Research Institute, City of Hope, Monrovia, CA 91016, USA; [email protected] 3 Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC), University of Salford, Greater Manchester M5 4WT, UK; fi[email protected] (M.F.); [email protected] (F.S.); [email protected] (M.P.L.) 4 Department of Biology, Ecology and Earth Sciences, Centre for Microscopy and Microanalysis (CM2), Transmission Electron Microscopy Laboratory, University of Calabria, Rende, 87036 Cosenza, Italy; [email protected] * Correspondence: [email protected] (D.S.); [email protected] (C.M.) These authors contributed equally to this work. y These authors share equal senior authorship. z Received: 7 November 2019; Accepted: 21 November 2019; Published: 25 November 2019 Abstract: Background: Resistance to endocrine treatments is a major clinical challenge in the management of estrogen receptor positive breast cancers.
    [Show full text]